Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV

Belpointe Asset Management LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 7.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,648 shares of the company’s stock after acquiring an additional 2,618 shares during the quarter. Belpointe Asset Management LLC’s holdings in AbbVie were worth $8,254,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new stake in AbbVie during the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at $39,000. Finally, Bear Mountain Capital Inc. increased its holdings in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $220.55 on Tuesday. The company has a market cap of $389.80 billion, a price-to-earnings ratio of 167.09, a PEG ratio of 0.90 and a beta of 0.36. The stock’s fifty day moving average price is $225.33 and its 200 day moving average price is $217.78. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio is currently 524.24%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent research reports. Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Bank of America raised their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $248.11.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.